# COMPARE ONE-PAGER (CROSS-INDUSTRY READY)

## HEADER
Ticker: INAF
Company: Indofarma Tbk
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
AsOf: 2024-07-01

## VALUATION
Market Cap: IDR 390.5 miliar
PER: -
PBV: -
Dividend Yield: 0%

## PROFITABILITY
Revenue Growth YoY: -70%
Net Profit Growth YoY: -15%
Net Margin: -159%
ROE: -
ROA: -

## BALANCE & CASH
DER: 2.2x
FCF: IDR -21.7 miliar

## SCORE (0â€“5 each; integers or 0.5 steps allowed)
ValuationScore: 0.5
ProfitabilityScore: 0
BalanceScore: 0
IncomeScore: 0
TotalScore: 0.5

## NOTES
Highlights:
- Revenue declined 70% YoY in FY 2024, with negative gross profit.
- Persistent negative free cash flow and capital deficiency.
- Large shareholder loans and high leverage.

Risks:
- Negative equity (capital deficiency) and high DER (>2x).
- No dividend, ongoing net losses, and negative FCF.
- Poor internal controls, history of fraud, and regulatory pricing pressure.

## METADATA
Source: Company filings, IDX, internal analysis
Period: FY 2024
LastUpdate: 2024-07-01